Current Implementation Rate of Tegafur/Uracil as Adjuvant Chemotherapy for Early-stage Non-small-cell Lung Cancer in Clinical Practice

Authors

Institutions

Publication Details

Journal
Haigan
Published
2025-10-20
DOI
https://doi.org/10.2482/haigan.65.911
Primary Topic
Lung Cancer Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Current Implementation Rate of Tegafur/Uracil as Adjuvant Chemotherapy for Early-stage Non-small-cell Lung Cancer in Clinical Practice

Yuichi Ichinose, Tamaki Kakuwa, Taisuke Ishii, Takahiro Higashi et al.
Haigan
Lung Cancer Research Studies
article

Current Implementation Rate of Tegafur/Uracil as Adjuvant Chemotherapy for Early-stage Non-small-cell Lung Cancer in Clinical Practice

Yuichi Ichinose, Tamaki Kakuwa, Taisuke Ishii, Takahiro Higashi, Go Naka, Tomone Watanabe, Masaaki Sato
article en

Abstract

No abstract available for this paper.
HaiganVol. 65(6)
Nihon University (JP), National Institute of Infectious Diseases (JP), Department of Health (IE), The University of Tokyo (JP)
Openalex Percentile: Top 57%
Lung Cancer Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Current Implementation Rate of Tegafur/Uracil as Adjuvant Chemotherapy for Early-stage Non-small-cell Lung Cancer in Clinical Practice — Yuichi Ichinose, Tamaki Kakuwa, et al. · Haigan (2025) | TGRS Research Map | TGRS